Total Payments
$3,322
2023 Payments
$129.89
Companies
2
Transactions
16
Medicare Patients
5,321
Medicare Billing
$537,018
Payment Breakdown by Category
Research$3,025 (91.1%)
Food & Beverage$296.89 (8.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,025 | 14 | 91.1% |
| Food and Beverage | $296.89 | 2 | 8.9% |
Payments by Type
Research
$3,025
14 transactions
General
$296.89
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $3,155 | 15 | $0 (2023) |
| Genentech, Inc. | $167.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $129.89 | 1 | Regeneron Pharmaceuticals, Inc. ($129.89) |
| 2019 | $1,906 | 9 | Regeneron Pharmaceuticals, Inc. ($1,739) |
| 2017 | $1,286 | 6 | Regeneron Pharmaceuticals, Inc. ($1,286) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/21/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $129.89 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $381.03 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $277.96 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $133.12 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $86.99 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $63.43 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 12/26/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $63.43 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 11/25/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $332.26 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 10/23/2019 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | — | In-kind items and services | $400.76 | Research |
| Study: A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration • Category: OPHTHALMOLOGY | ||||||
| 07/27/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $167.00 | General |
| Category: None | ||||||
| 05/16/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $348.00 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
| 05/16/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $118.03 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
| 05/16/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $82.13 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
| 05/16/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $54.64 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
| 05/09/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $230.85 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
| 03/28/2017 | Regeneron Pharmaceuticals, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | — | In-kind items and services | $452.40 | Research |
| Study: A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY • Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration | Regeneron Pharmaceuticals, Inc. | $1,739 | 8 |
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $1,286 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,435 | 3,544 | $746,820 | $144,231 |
| 2022 | 15 | 1,255 | 2,690 | $599,957 | $119,212 |
| 2021 | 16 | 1,396 | 2,507 | $679,211 | $133,300 |
| 2020 | 14 | 1,235 | 2,365 | $747,547 | $140,275 |
Total Patients
5,321
Total Services
11,106
Medicare Billing
$537,018
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67028 | Injection of drug into eye | Office | 2023 | 161 | 657 | $281,751 | $50,982 | 18.1% |
| 92134 | Imaging of retina | Office | 2023 | 444 | 1,080 | $105,408 | $18,252 | 17.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 263 | 319 | $46,983 | $14,275 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 149 | 165 | $37,112 | $11,354 | 30.6% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Office | 2023 | 13 | 17 | $44,795 | $9,413 | 21.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 90 | 90 | $32,260 | $8,549 | 26.5% |
| 66986 | Exchange of prosthetic lens | Office | 2023 | 12 | 12 | $36,780 | $7,598 | 20.7% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Office | 2023 | 14 | 14 | $42,560 | $6,164 | 14.5% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Office | 2023 | 11 | 13 | $24,050 | $5,409 | 22.5% |
| 66682 | Suture of iris and lens | Office | 2023 | 15 | 15 | $36,600 | $4,086 | 11.2% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 11 | 13 | $13,910 | $2,921 | 21.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 56 | 672 | $26,912 | $2,318 | 8.6% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 55 | 73 | $9,855 | $1,615 | 16.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 24 | 32 | $4,785 | $753.69 | 15.8% |
| 92250 | Photography of the retina | Office | 2023 | 28 | 29 | $2,320 | $442.26 | 19.1% |
| J3590 | Unclassified biologics | Office | 2023 | 89 | 343 | $738.36 | $97.40 | 13.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 146 | 586 | $239,303 | $44,596 | 18.6% |
| 92134 | Imaging of retina | Office | 2022 | 412 | 992 | $95,765 | $17,563 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 240 | 300 | $40,349 | $12,866 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 132 | $26,315 | $9,305 | 35.4% |
| 66986 | Exchange of prosthetic lens | Office | 2022 | 11 | 12 | $36,240 | $8,018 | 22.1% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Office | 2022 | 15 | 18 | $32,760 | $6,934 | 21.2% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Office | 2022 | 14 | 14 | $41,930 | $6,563 | 15.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $18,490 | $5,022 | 27.2% |
| 66682 | Suture of iris and lens | Office | 2022 | 11 | 11 | $26,620 | $3,043 | 11.4% |
About Dr. Matthew Ohr, MD
Dr. Matthew Ohr, MD is a Ophthalmology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023199841.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Ohr, MD has received a total of $3,322 in payments from pharmaceutical and medical device companies, with $129.89 received in 2023. These payments were reported across 16 transactions from 2 companies. The most common payment nature is "" ($3,025).
As a Medicare-enrolled provider, Ohr has provided services to 5,321 Medicare beneficiaries, totaling 11,106 services with total Medicare billing of $537,018. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Columbus, OH
- Active Since 10/18/2006
- Last Updated 01/21/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1023199841
Products in Payments
- EYLEA (Biological) $1,869
- EYLEA AFLIBERCEPT INJECTION (Biological) $1,286
- Non-Covered Product (Drug) $167.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Columbus
Alice Epitropoulos, M.d, M.D
Ophthalmology — Payments: $611,779
Ophthalmology $611,779
Steven Katz, Md, MD
Ophthalmology — Payments: $202,492
Ophthalmology $202,492
Stephen Beaty, M.d, M.D
Ophthalmology — Payments: $36,455
Ophthalmology $36,455
Lisa Borkowski, Md, MD
Ophthalmology — Payments: $24,461
Ophthalmology $24,461
Raymond Cho, Md, MD
Ophthalmology — Payments: $23,167
Ophthalmology $23,167
Bret Crumpton, D.o, D.O
Ophthalmology — Payments: $12,382
Ophthalmology $12,382